scholarly article | Q13442814 |
P356 | DOI | 10.1111/NEUP.12405 |
P698 | PubMed publication ID | 28856744 |
P50 | author | Anamarija M Perry | Q88882568 |
P2093 | author name string | Weiwei Zhang | |
Marc R Del Bigio | |||
Fausto Loberiza | |||
Timothy C Greiner | |||
Lynette M Smith | |||
Mei Zheng | |||
David Szwajcer | |||
Philip Bierman | |||
Michel R Nasr | |||
P2860 | cites work | The somatic genomic landscape of glioblastoma | Q28300185 |
Oncogenically active MYD88 mutations in human lymphoma | Q28301648 | ||
The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin's lymphoma | Q33608166 | ||
Mutational analysis of primary central nervous system lymphoma | Q34104139 | ||
B-cell receptor signaling in diffuse large B-cell lymphoma | Q35218042 | ||
Diagnosis and treatment of central nervous system involvement in non-Hodgkin's lymphoma | Q36220001 | ||
Primary lymphoma of the central nervous system: just DLBCL or not? | Q37273021 | ||
Targeting pathological B cell receptor signalling in lymphoid malignancies | Q38085501 | ||
Predictive biomarkers in adult gliomas: the present and the future | Q38146515 | ||
Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas | Q39578940 | ||
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma | Q40182586 | ||
Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature | Q41460237 | ||
High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites | Q41960712 | ||
Current and emerging pharmacotherapies for primary CNS lymphoma | Q42126754 | ||
A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. | Q42285217 | ||
Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status | Q43258495 | ||
CpG island methylation of tumor-related genes in three primary central nervous system lymphomas in immunocompetent patients | Q44378625 | ||
MGMT promoter methylation in plasma of glioma patients receiving temozolomide | Q45088198 | ||
High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma | Q45183858 | ||
Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas. | Q48109166 | ||
MGMT promoter methylation and correlation with protein expression in primary central nervous system lymphoma | Q48656685 | ||
Genomic characterization of primary central nervous system lymphoma | Q49011918 | ||
CD79B and MYD88 mutations in diffuse large B-cell lymphoma | Q51121788 | ||
Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia. | Q51329192 | ||
Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations. | Q54187253 | ||
O⁶-methylguanine-DNA methyltransferase promoter methylation in 45 primary central nervous system lymphomas: quantitative assessment of methylation and response to temozolomide treatment. | Q54345375 | ||
P433 | issue | 6 | |
P304 | page(s) | 509-516 | |
P577 | publication date | 2017-08-30 | |
P1433 | published in | Neuropathology | Q15761930 |
P1476 | title | Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma | |
P478 | volume | 37 |
Q92283033 | Genetic alterations and their clinical implications in DLBCL |
Q92253999 | MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis |
Q47118882 | Mutational profile of primary breast diffuse large B-cell lymphoma |
Q47162060 | New developments in the pathology of malignant lymphoma. A review of the literature published from September-August 2017. |
Q55712161 | Primary extra-nodal diffuse large B-cell lymphoma: A prognostic analysis of 141 patients. |
Search more.